22.04.2018
Fresenius Medical Care AG & Co. KGaA DE0005785802
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA adjusts its 2018 revenue growth target and confirms its net income growth target
DGAP-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Change in
Forecast
Fresenius Medical Care AG & Co. KGaA adjusts its 2018 revenue growth target
and confirms its net income growth target
22-Apr-2018 / 16:52 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Fresenius Medical Care, the world's largest provider of dialysis products
and services, has decided to adjust its 2018 revenue growth target from
around 8 percent to a range of 5 to 7 percent at constant currency [1].
The main reason for this adjustment is the Company's recent reassessment of
dosing of calcimimetic drugs in its dialysis service business in the United
States. The reduction in dosing was faster than assumed and results in a
lower than expected revenue contribution.
At the same time, Fresenius Medical Care reconfirms its 2018 net income
growth target of 13 to 15 percent at constant currency. The Company's 2018
targets continue to exclude the effects of the planned acquisition of
NxStage Medical, Inc. and exclude the effects of the divestiture of Sound
Inpatient Physicians Holdings, LLC.
Final financial results for the first quarter 2018 will be published, as
scheduled, on 3 May 2018.
_____________
[1] 2017 adjusted for the effect of IFRS 15 implementation
Fresenius Medical Care is the world's largest provider of products and
services for individuals with renal diseases of which around 3.2 million
patients worldwide regularly undergo dialysis treatment. Through its network
of 3,752 dialysis clinics, Fresenius Medical Care provides dialysis
treatments for 320,960 patients around the globe. Fresenius Medical Care is
also the leading provider of dialysis products such as dialysis machines or
dialyzers. Along with the core business, the company focuses on expanding
the range of related medical services in the field of Care Coordination.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and
on the New York Stock Exchange (FMS).
For more information visit the Company's website at
www.freseniusmedicalcare.com.
---------------------------------------------------------------------------
22-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: [email protected]
Internet: www.freseniusmedicalcare.com
ISIN: DE0005785802
WKN: 578580
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; NYSE
End of Announcement DGAP News Service
---------------------------------------------------------------------------
677311 22-Apr-2018 CET/CEST
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 können Sie bei EQS abrufen
Medtech , 578580 , FME , XETR:FME